ImmuSAFE™ enables the determination of the target epitopes, titres and Ig class/sub-class (IgG, IgA, IgM; IgG1-4) of antibodies produced across all stages of COVID-19 infection, from initial exposure, disease development, post-recovery or post-vaccination. These results will provide critical insights on whether individuals have high titres of potentially neutralising antibodies against SARS CoV-2 that may protect against reinfection or whether booster vaccinations are required. ImmuSAFE™ is a lab-based biochip test that utilises patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. The test contains more than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions. Cross-reactivity between immunogenic regions of SARS-CoV-2 and other coronaviruses may lead to an overestimation of sero-prevalence in a given population. ImmuSAFE™ is designed to reduce cross-reactivity by targeting multiple SARS-CoV-2 specific domains, resulting in fewer false positives, and a more accurate determination of sero-prevalence. The ImmuSAFE™ product range also includes other biochip-based tests that incorporate additional viral antigens such as: SARS-CoV-2 Envelope, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.
